EBEmma Bondy-Chorney

Emma Bondy-Chorney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emma Bondy-Chorney has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Jocelyn Côté

    Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

    6 shared publications
  • Bernard J. Jasmin

    Department of Cellular and Molecular Medicine, University of Ottawa, Centre for Neuromuscular Disease, Ottawa, Ontario, K1H 8L1, Canada

    4 shared publications
  • Michael Downey

    Ottawa Institute of Systems Biology, Ottawa, Ontario, Canada

    4 shared publications
  • Aymeric Ravel-Chapuis

    School of Pharmaceutical Sciences, Faculty of Medicine University of Ottawa Ottawa Ontario Canada

    3 shared publications
  • Tara E. Crawford Parks

    Department of Cellular and Molecular Medicine, Centre for Neuromuscular Disease, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

    3 shared publications
  • Yuka Sai

    Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

    3 shared publications

Latest Publications

  • Open Access

    A Broad Response to Intracellular Long-Chain Polyphosphate in Human Cells

    by Emma Bondy-Chorney, Iryna Abramchuk, Rawan Nasser, Charlotte Holinier, Alix Denoncourt, Kanchi Baijal, Liam McCarthy, Mireille Khacho, Mathieu Lavallée-Adam, Michael Downey


  • Open Access

    A broad response to intracellular long-chain polyphosphate in human cells

    by Emma Bondy-Chorney, Iryna Abramchuk, Rawan Nasser, Charlotte Holinier, Alix Denoncourt, Kanchi Baijal, Liam McCarthy, Mireille Khacho, Mathieu Lavallée-Adam, Michael Downey

    Polyphosphates (PolyP) are composed of long chains of inorganic phosphates linked together by phosphoanhydride bonds. They are found in all kingdoms of life, playing roles in cell growth, infection, and blood coagulation. A resurgence in interest in polyP has shown links to diverse aspects of human disease. However, unlike in bacteria and lower eukaryotes, the mammalian enzymes responsible for polyP metabolism are not known. Many studies have resorted to adding polyP to cell culture media, but it is not clear if externally applied polyP enters the cell to impact signaling events or whether their effect is mediated exclusively by extracellular receptors. For the first time, we use RNA-seq and mass spectrometry to define a broad impact of polyP produced inside of mammalian cells via ectopic expression of the E. coli polyP synthetase Ppk1. RNA-seq demonstrates that Ppk1 expression impacts expression of over 350 genes enriched for processes related to transcription and cell motility. Analysis of proteins via label-free mass spectrometry identified over 100 changes with functional enrichment in cell migration. Follow up work suggests a role for internally-synthesized polyP in promoting activation of mTOR and ERK1/2-EGR1 signaling pathways implicated in cell growth and stress. Finally, fractionation analysis shows that polyP accumulated in multiple cellular compartments and was associated with the relocalization several nuclear/cytoskeleton proteins, including chromatin bound proteins DEK, TAF10, GTF2I and translation initiation factor eIF5b. Our work is the first to demonstrate that internally produced polyP can activate diverse signaling pathways in human cells. Significance Statement: For many years following its discovery in 1890, polyphosphates (polyP) were dismissed as evolutionary fossils. Best understood for its role in bacteria and yeast, our understanding of polyP in mammals remains rudimentary because the enzymes that synthesize and degrade polyP in mammalian systems are currently unknown. In our work, we carried out large-scale transcriptome and proteome approaches on human cells designed to accumulate internally produced polyP via ectopic expression of a bacterial polyP synthetase. Our work is the first to systematically assess the impact of increased intracellular polyP.


  • Open Access

    SIRT3 controls brown fat thermogenesis by deacetylation regulation of pathways upstream of UCP1

    by Rajaa Sebaa, Jeff Johnson, Chantal Pileggi, Michaela Norgren, Jian Xuan, Yuka Sai, Qiang Tong, Izabella Krystkowiak, Emma Bondy-Chorney, Norman E. Davey, et al.


  • Nonhistone targets of KAT2A and KAT2B implicated in cancer biology

    by Emma Bondy-Chorney, Alix Denoncourt, Yuka Sai, Michael Downey

    Lysine acetylation is a critical post-translation modification that can impact a protein’s localization, stability, and function. Originally thought to only occur on histones, we now know thousands of nonhistone proteins are also acetylated. In conjunction with many other proteins, lysine acetyltransferases (KATs) are incorporated into large protein complexes that carry out these modifications. In this review we focus on the contribution of two KATs, KAT2A and KAT2B, and their potential roles in the development and progression of cancer. Systems biology demands that we take a broad look at protein function rather than focusing on individual pathways or targets. As such, in this review we examine KAT2A/2B-directed nonhistone protein acetylations in cancer in the context of the 10 “Hallmarks of Cancer”, as defined by Hanahan and Weinberg. By focusing on specific examples of KAT2A/2B-directed acetylations with well-defined mechanisms or strong links to a cancer phenotype, we aim to reinforce the complex role that these enzymes play in cancer biology.


  • Open Access

    A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy

    by Maneka Chitiprolu, Chantal Jagow, Veronique Tremblay, Emma Bondy-Chorney, Geneviève Paris, Alexandre Savard, Gareth Palidwor, Francesca A. Barry, Lorne Zinman, Julia Keith, et al.

    Mutations in proteins like FUS which cause Amyotrophic Lateral Sclerosis (ALS) result in the aberrant formation of stress granules while ALS-linked mutations in other proteins impede elimination of stress granules. Repeat expansions in C9ORF72, the major cause of ALS, reduce C9ORF72 levels but how this impacts stress granules is uncertain. Here, we demonstrate that C9ORF72 associates with the autophagy receptor p62 and controls elimination of stress granules by autophagy. This requires p62 to associate via the Tudor protein SMN with proteins, including FUS, that are symmetrically methylated on arginines. Mice lacking p62 accumulate arginine-methylated proteins and alterations in FUS-dependent splicing. Patients with C9ORF72 repeat expansions accumulate symmetric arginine dimethylated proteins which co-localize with p62. This suggests that C9ORF72 initiates a cascade of ALS-linked proteins (C9ORF72, p62, SMN, FUS) to recognize stress granules for degradation by autophagy and hallmarks of a defect in this process are observable in ALS patients.


  • Open Access

    A Screen for Candidate Targets of Lysine Polyphosphorylation Uncovers a Conserved Network Implicated in Ribosome Biogenesis

    by Amanda Bentley-DeSousa, Charlotte Holinier, Houman Moteshareie, Yi-Chieh Tseng, Sam Kajjo, Christine Nwosu, Giuseppe Federico Amodeo, Emma Bondy-Chorney, Yuka Sai, Adam Rudner, et al.


  • Open Access

    Muscle-specific expression of the RNA-binding protein Staufen1 induces progressive skeletal muscle atrophy via regulation of phosphatase tensin homolog

    by Tara E. Crawford Parks, Aymeric Ravel-Chapuis, Emma Bondy-Chorney, Jean-Marc Renaud, Jocelyn Côté, Bernard J. Jasmin

    Converging lines of evidence have now highlighted the key role for post-transcriptional regulation in the neuromuscular system. In particular, several RNA-binding proteins are known to be misregulated in neuromuscular disorders including myotonic dystrophy type 1, spinal muscular atrophy and amyotrophic lateral sclerosis. In this study, we focused on the RNA-binding protein Staufen1, which assumes multiple functions in both skeletal muscle and neurons. Given our previous work that showed a marked increase in Staufen1 expression in various physiological and pathological conditions including denervated muscle, in embryonic and undifferentiated skeletal muscle, in rhabdomyosarcomas as well as in myotonic dystrophy type 1 muscle samples from both mouse models and humans, we investigated the impact of sustained Staufen1 expression in postnatal skeletal muscle. To this end, we generated a skeletal muscle-specific transgenic mouse model using the muscle creatine kinase promoter to drive tissue-specific expression of Staufen1. We report that sustained Staufen1 expression in postnatal skeletal muscle causes a myopathy characterized by significant morphological and functional deficits. These deficits are accompanied by a marked increase in the expression of several atrophy-associated genes and by the negative regulation of PI3K/AKT signaling. We also uncovered that Staufen1 mediates PTEN expression through indirect transcriptional and direct post-transcriptional events thereby providing the first evidence for Staufen1-regulated PTEN expression. Collectively, our data demonstrate that Staufen1 is a novel atrophy-associated gene, and highlight its potential as a biomarker and therapeutic target for neuromuscular disorders and conditions.


  • Open Access

    Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier

    by Emma Bondy-Chorney, Tara E. Crawford Parks, Aymeric Ravel-Chapuis, Roscoe Klinck, Lynda Rocheleau, Martin Pelchat, Benoit Chabot, Bernard J. Jasmin, Jocelyn Côté

    Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by an expansion of CUG repeats in the 3' UTR of the DMPK gene. The CUG repeats form aggregates of mutant mRNA, which cause misregulation and/or sequestration of RNA-binding proteins, causing aberrant alternative splicing in cells. Previously, we showed that the multi-functional RNA-binding protein Staufen1 (Stau1) was increased in skeletal muscle of DM1 mouse models and patients. We also showed that Stau1 rescues the alternative splicing profile of pre-mRNAs, e.g. the INSR and CLC1, known to be aberrantly spliced in DM1. In order to explore further the potential of Stau1 as a therapeutic target for DM1, we first investigated the mechanism by which Stau1 regulates pre-mRNA alternative splicing. We report here that Stau1 regulates the alternative splicing of exon 11 of the human INSR via binding to Alu elements located in intron 10. Additionally, using a high-throughput RT-PCR screen, we have identified numerous Stau1-regulated alternative splicing events in both WT and DM1 myoblasts. A number of these aberrant ASEs in DM1, including INSR exon 11, are rescued by overexpression of Stau1. However, we find other ASEs in DM1 cells, where overexpression of Stau1 shifts the splicing patterns away from WT conditions. Moreover, we uncovered that Stau1-regulated ASEs harbour Alu elements in intronic regions flanking the alternative exon more than non-Stau1 targets. Taken together, these data highlight the broad impact of Stau1 as a splicing regulator and suggest that Stau1 may act as a disease modifier in DM1. Myotonic Dystrophy Type 1 (DM1) is an inherited disorder affecting many systems, including skeletal muscle, heart, eyes and endocrine system. DM1 is known as a ‘trinucleotide repeat disorder’ because it is caused by an abnormal expansion of a highly repeated motif within the DMPK locus. Such an expansion results in the expression of a ‘toxic RNA’, which causes misregulation of proteins involved in many essential cellular pathways. Research efforts have largely focused on misregulation of a very few splicing regulators that can be linked with many defects observed in the pathology. We have recently uncovered that the multifunctional RNA-binding protein Staufen1 is increased in DM1, and that it is capable of rescuing selected defects in DM1 cells, including alternative splicing of the INSR pre-mRNA, which is linked with insulin resistance. Given the potential impact of this novel function for Staufen1, we investigated the mechanism by which it regulates splicing, and determined that it mediates its effects through binding to conserved genomic repetitive sequences called Alu elements. We also uncovered that Staufen1 influences the splicing of numerous genes in DM1 patient cells, predictive to either improve or worsen the pathology, thus identifying Staufen1 as a novel disease modifier in DM1.


  • Open Access

    Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I

    by Emma Bondy-Chorney, Tara E. Crawford Parks, Aymeric Ravel-Chapuis, Bernard J. Jasmin, Jocelyn Côté

    In a recent issue of PLOS Genetics, we reported that the double-stranded RNA-binding protein, Staufen1, functions as a disease modifier in the neuromuscular disorder Myotonic Dystrophy Type I (DM1). In this work, we demonstrated that Staufen1 regulates the alternative splicing of exon 11 of the human Insulin Receptor, a highly studied missplicing event in DM1, through Alu elements located in an intronic region. Furthermore, we found that Staufen1 overexpression regulates numerous alternative splicing events, potentially resulting in both positive and negative effects in DM1. Here, we discuss our major findings and speculate on the details of the mechanisms by which Staufen1 could regulate alternative splicing, in both normal and DM1 conditions. Finally, we highlight the importance of disease modifiers, such as Staufen1, in the DM1 pathology in order to understand the complex disease phenotype and for future development of new therapeutic strategies.